

The Fight Against Pancreatic Cancer

April 2016 Efrat Dotan, M.D.


Assistant Professor Department of medical oncology Fox Chase Cancer Center



<u>Overview</u>

- Epidemiology/Biology
- Diagnosis
- Early stage disease
 - Surgical treatments
 - Chemotherapy/Radiation treatments
- Advanced stage disease
 - Chemotherapy treatments
- Future Research







				niology			
Estimated New Cases							
			Males	Females			
Prostate	180,890	21%		Breast	246,660	29%	
Lung & bronchus	117,920	14%		Lung & bronchus	106,470	13%	
Colon & rectum	70,820	8%		Colon & rectum	63,670	8%	
Urinary bladder	58,950	7%		Uterine corpus	60,050	7%	
Melanoma of the skin	46,870	6%		Thyroid	49,350	6%	
Non-Hodgkin lymphoma	40,170	5%		Non-Hodgkin lymphoma	32,410	4%	
Kidney & renal pelvis	39,650	5%		Melanoma of the skin	29,510	3%	
Oral cavity & pharynx	34,780	4%		Leukemia	26,050	3%	
Leukemia	34,090	4%		Pancreas	25,400	3%	
Liver & intrahepatic bile duct	28,410	3%		Kidney & renal pelvis	23,050	3%	
All Sites	841,390	100%		All Sites	843,820	100%	
Estimated Deaths							
			Males	Females			
Lung & bronchus	85,920	27%		Lung & bronchus	72,160	26%	
Prostate	26,120	8%		Breast	40,450	14%	
Colon & rectum	26,020	8%		Colon & rectum	23,170	8%	
Pancreas	21,450	7%		Pancreas	20,330	7%	
Liver & intrahepatic bile duct	18,280	6%		Ovary	14,240	5%	
Leukemia	14,130	4%		Uterine corpus	10,470	4%	
Esophagus	12,720	4%		Leukemia	10,270	4%	
Urinary bladder	11,820	4%		Liver & intrahepatic bile duct	8,890	3%	
Non-Hodgkin lymphoma	11,520	4%		Non-Hodgkin lymphoma	8,630	3%	
	9.440	3%		Brain & other nervous system	6.610	2%	

Epidemiology

- - Estimated 53,000 new cases diagnosed yearly in the US.
 - Males- 27,670
 - Females 25,400
 - Pancreatic Cancer Represent 3% of all new cancer cases in the U.S.



Siegel et al, 2016 SEER Cancer Statistics Review, 1975-2012, National Cancer Institute



SEER Cancer Statistics Review, 1975-2012, National Cancer Institute




Risk factors





- Smoking
- Overweight
- Personal history of diabetes
- Personal history of chronic pancreatitis – inflammation to the pancreas
- Family history of pancreatic cancer
- Hereditary conditions

SEER Cancer Statistics Review, 1975-2012, National Cancer Institute









	1975-1977	1987-1989	2005-2011
5 year survival	3%	4%	8%
al at al. 2016	·		

Siegel et al, 2016

Diagnosis



Challenges in Early Diagnosis:

- Usually there are no symptoms or signs in early stages of the disease.
- Many of the signs and symptoms are not specific (weakness, abdominal discomfort, loss of appetite)
- The pancreas is hidden behind other organs and hard to examine.

Siegel et al, 2016



Signs & Symptoms

- Asthenia (weakness) 86%
- Weight loss and Anorexia (no appetite)- 85%
- Abdominal pain 79%
- Epigastric pain (stomach) 71%
- Dark urine 59%
- Jaundice 56 %
- Nausea 51%
- Back pain 49%
- Diarrhea- 44%
- Vomiting 33%
- Steatorrhea (fatty stools)- 25%
- Thrombophlebitis 3%
- Hepatomegaly (large liver) 39%
- Epigastric mass 15%
- Ascites (abdominal fluid) 5%




Diagnosis


Blood tests:


- Elevation of liver function tests.
- Elevation of tumor marker CA19-9

Imaging:

- Ultrasound
- CT Scan
- MRI
- PET-CT













CT guided biopsy for patients with metastatic disease.





Treatment – Early stage


The Memoirs of Allen Oldfather Whipple The man behind the Whipple operation





Allen Oldfather Whipple (1881- 1963)

- Only curative option is surgical resection.
- Removal of the gallbladder, bile ducts, part of the duodenum and head of the pancreas.
- Modification to the surgery have been developed to decrease morbidity.
- Minimally invasive techniques are feasible











Current peri-operative mortality is approximately 4%.


Winter JM. et al. Annals of surgery 2012






Bilimoria K. et al. Annals of surgery 2007







TT FOX CHASE CANCER CENTER TEMPLE HEALTH

Berger A. 2008


Adjuvant therapy

CONKO study:

Collaborative, multi-institutional, randomized, controlled trial have demonstrated benefit to chemotherapy with gemcitabine for 6 months after surgery.



Oettle et al. JAMA. 2007






Chemo-radiation:

Multiple studies have shown some improvement with the addition of chemo/radiation to the post operative therapy.

There is an ongoing debate regarding the benefit.

In the US often used.



Adjuvant therapy

Meta-analysis:

•Evaluation of all studied performed with chemotherapy with and without radiation, found chemotherapy with Gemcitabine or Fluorouracil to be the most effective in reducing mortality by about 1/3.

Observa	tion Chemoradiation	Gemcitabine	Fluorouracil	Chemoradiation plus fluorouracil	Chemoradiation plus gemcitabine
Least		Tox	icity		Most
Observa	tion Chemoradiation	Gemcitabine	Fluorouracil	Chemoradiation plus fluorouracil	Chemoradiation plus gemcitabine
Worst		Sur	vival		Best
Wei-Ch	ih Liao et al. Lancet	Oncology2013	3		CANCER CENTER TEMPLE HEALTH

Wei-Chih Liao et al. Lancet Oncology2013



Ongoing clinical research:

- 135 studies listed in clinicaltrials.gov for adjuvant therapy for resected pancreatic cancer.
- Large studies in Europe and the US using more • aggressive chemotherapy regimens in comparison to single agent gemcitabine.







Borderline resectable

- Definition varies mostly in cases with large tumors in close proximity to local blood vessels.
- Tumors encasing the vessel were in the past considered unresectable. However, with vascular re-construction some of these cases can go to surgery.
- Tumor shrinkage with chemotherapy or radiation before surgery used more often – Neoadjuvant therapy.



Neoadjuvant therapy

- About 30-40% of patients are candidates.
- Optimal therapy is controversial.
- Goal Shrink the tumor and allow for a resection.

Study	# patients	Regimen	<pre># of patients with surgery</pre>
Vasile E. 2012	15	FOLFIRINOX+RT	5
Gunturu K, 2013	16	FOLFIRINOX	2
Marthey L, 2015	77	FOLFIRINOX+RT	25
Blazer M, 2015	43	FOLFIRINOX+RT	19
Mellon E, 2015	159	FOLFIRINOX+Gem/ Abraxane+RT	59
Sadot E, 2015	101	FOLFIRINOX+RT	16
			FOA CHAS CANCER CENTE TEMPLE HEALT

Neoadjuvant therapy

Radiation:

- Controversial results regarding the benefit of radiation from clinical trials.
- Often added to the regimen.
- Benefit:
 - -Local control
 - -Good tolerance
 - -Better chance of getting


The treatment pre-op.




Metastatic disease

Goals:

- Drug delivery to all sites.
- Palliative therapy.
- Prolonging survival.
- Improving quality of life.






6 mm			Advai	nces.		
1985	1990	1995	2000	2005	2010	2015
Best s	upportive	care — 5-FU—				\rightarrow
			Gemcital Capec	bine ——		\rightarrow

Conclusion from multiple papers (1990s - early 2000s):

"The only justification for subjecting a patient with advanced pancreatic carcinoma to chemotherapy is the entry of such a patient into a clinical research trial that at least provides the hope that something of value may be accomplished."



Gemcitabine approved in 1997 for first-line therapy of advanced pancreatic cancer Clinical benefit: 23.8% vs. 4.8%



	The	ne	kt phase)	
		Pha	ase II		
Drugo	tested		# motionto	Deputte	

Drugs tested	# patients	Results
Gemcitabine +/- cisplatin	192	No difference
Gemcitabine +/- oxaliplatin	313	No difference
Gemcitabine +/- 5-FU	322	No difference
Gemcitabine +/- capecitabine)	533	No difference
Gemcitabine +/- pemetrexed	565	No difference
Gemcitabine +/- irinotecan	360	No difference
Gemcitabine +/- exatecan	349	No difference


None demonstrated statistically significant


improvement in survival


Boeck and Heinemann, 2008.



_/	Th	ie no	ext pha	se
		Pł	nase III	
	Drugs tested		# Patients	Results
	Gemcitabine +/- Marimas	stat	239	No difference
	Gemcitabine +/- Tipifarni	b	688	No difference
	Gemcitabine +/- Erlotinib		569	Minimal improvement with Erlotinib
	Gemcitabine +/- Bevaciz	umab	602	No difference
	Gemcitabine +/- Cetuxim	ab	735	No difference
	Gemcitabine +/- Axitinib		632	No difference
	Bramhall et al, 2002; Van Cutsem et al, 2 Philip et al, 2010; Kindler et al, 2011.	004; Moore	et al, 2007; Kindler et	al, 2010; FOX CHASE CANCER CENTER TEMPE HEATTH













Pre - treatment

Post - treatment







Improvement in quality of life measures:

- Improvement in symptoms fatigue, pain, anorexia
- Physical and cognitive function
- Global Health Scores


Gourgou-Bourgade et al, 2013.






Event	FOLFIRINOX (n=171)	Gemcitabine (n=171)	P value
Hematologic			
Neutropenia	45.7%*	21.0%	< 0.001
Febrile neutropenia	5.4%	1.2%	0.03
Thrombocytopenia	9.1%	3.6%	0.04
Non-hematologic			
Fatigue	23.6%	17.8%	NS
Vomiting	14.5%	8.3%	NS
Diarrhea	12.7%	1.8%	< 0.001
Sensory neuropathy	9.0%	0.0%	<0.001
Conroy et al, 2011.			T Fox Cha

Conroy et al, 2011.





Von Hoff et al, 2013.


Safet	ty	
Preferred Term	<i>nab</i> -P + Gem (n = 421)	Gem (n = 402)
Grade ≥3 Hematologic AE, ª %		
Neutropenia	38	27
Leukopenia	31	16
Thrombocytopenia	13	9
Anemia	13	12
Pts Who Received Growth Factors, %	26	15
Febrile Neutropenia, ^b %	3	1
Grade ≥3 Nonhematologic AE ^b in >5% Pts, %		
Fatigue	17	7
Peripheral Neuropathy ^c	17	<1
Diarrhea	6	1
Grade ≥3 Neuropathy		
Time to Onset, median days	140	113
Time to Improvement by 1 Grade, median days	21	29
Time to Improvement to Grade ≤1, median days	29	
Pts Who Resumed <i>nab</i> -P, %	44	

Von Hoff et al, 2013.





T FOX CHASE















Clinical trials




Ongoing clinical research:

- Over 200 studies listed in <u>clinicaltrials.gov</u> for metastatic pancreatic cancer.
- Most studies involving combination of Gemcitabine/abraxane + Drug X.
- At FCCC 3 ongoing studies with Gemcitabine +Abraxane +Drug X.
 - Wee Inhibitor \rightarrow AZ1775
 - Wnt inhibitor → Vantictumab
 - Wnt inhibitor \rightarrow Ipafricept








- Prior phase I trial of CRS-207 showed markedly improved survival (17 months) in 3 pancreatic cancer patients who had previously undergone 'boost' with GVAX vaccine.
- o Primary objective: overall survival


Dung T. Le et al. JCO 2014







Dung T. Le et al. JCO 2014





- There is real optimism in the treatment of this disease!!
- Survival has clearly improved for metastatic disease and localized disease.
- Renewed interest in drug development has invigorated clinical trials.
- Enrollment in clinical trials is highly encouraged!





- Over 170 pancreatic cancer specific studies listed in Clinical Trial Finder.
- Over 115 pancreatic cancer specific studies listed in Clinical Trial Finder for metastatic pancreatic cancer.

